{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:41:56Z","timestamp":1790386916489,"version":"4.1.0"},"reference-count":34,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"vor","delay-in-days":138,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/L017180\/1"],"award-info":[{"award-number":["BB\/L017180\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Novartis Institute for Tropical Diseases","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New tools are required to ensure the adequate control of the neglected tropical disease human African trypanosomiasis. Annual reports of infection have recently fallen to fewer than 5000 cases per year; however, current therapies are hard to administer and have safety concerns and, hence, are far from ideal. Trypanosome alternative oxidase is an exciting target for controlling the infection; it is unique to the parasite, and inhibition of this enzyme with the natural product ascofuranone has shown to clear in vivo infections. We report the synthesis and associated structure activity relationships of inhibitors based upon this natural product with correlation to T.\u00a0b.\u00a0brucei growth inhibition in an attempt to generate molecules that possess improved physicochemical properties and potential for use as new treatments for human African trypanosomiasis.<\/jats:p>","DOI":"10.1021\/acsinfecdis.7b00218","type":"journal-article","created":{"date-parts":[[2018,1,21]],"date-time":"2018-01-21T11:22:13Z","timestamp":1516533733000},"page":"592-604","source":"Crossref","is-referenced-by-count":13,"title":["Toward More Drug Like Inhibitors of Trypanosome Alternative\nOxidase"],"prefix":"10.1021","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-9180","authenticated-orcid":true,"given":"Ryan A.","family":"West","sequence":"first","affiliation":[{"name":"University of Sussex , , , ,","place":["Brighton, United Kingdom, BN1 9QJ"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cunningham","sequence":"additional","affiliation":[{"name":"University of Sussex , , , ,","place":["Brighton, United Kingdom, BN1 9QJ"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis E.","family":"Pennicott","sequence":"additional","affiliation":[{"name":"University of Sussex , , , ,","place":["Brighton, United Kingdom, BN1 9QJ"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa P. S.","family":"Rao","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Tropical Diseases , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608-2916"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon E.","family":"Ward","sequence":"additional","affiliation":[{"name":"University of Sussex , , , ,","place":["Brighton, United Kingdom, BN1 9QJ"]},{"name":"Cardiff University , , Park Place, , ,","place":["Cardiff, United Kingdom, CF10 3AT"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,1,21]]},"reference":[{"key":"2026090108010904000_cit1","volume-title":"Control and surveillance\nof human African trypanosomiasis","author":"World Health Organisation.","year":"2013"},{"issue":"10","key":"2026090108010904000_cit2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2174\/156802611795429167","article-title":"State of the Art in African Trypanosome\nDrug Discovery","volume":"11","author":"Jacobs","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"2026090108010904000_cit3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1473-3099(13)70191-9","article-title":"Do we need new drugs against human\nAfrican trypanosomiasis?","volume":"13","author":"Stich","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"1\u20132","key":"2026090108010904000_cit4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2007.02.004","article-title":"Drugs and drug resistance in African trypanosomiasis","volume":"10","author":"Delespaux","year":"2007","journal-title":"Drug Resist. Updates"},{"issue":"3","key":"2026090108010904000_cit5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","article-title":"Drug resistance in\nAfrican trypanosomiasis: the melarsoprol and pentamidine story","volume":"29","author":"Baker","year":"2013","journal-title":"Trends Parasitol."},{"key":"2026090108010904000_cit6","first-page":"28","volume-title":"Preliminary\nreport on the tsetse fly\ndisease or nagana in Zululand","author":"Bruce","year":"1895"},{"key":"2026090108010904000_cit7","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent\nDevelopments in Drug Discovery for Leishmaniasis\nand Human African Trypanosomiasis","volume":"114","author":"Nagle","year":"2014","journal-title":"Chem. Rev."},{"key":"2026090108010904000_cit8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1242\/jcs.01649","article-title":"The developmental\ncell biology of Trypanosoma brucei","volume":"118","author":"Matthews","year":"2005","journal-title":"J. Cell\nSci."},{"issue":"1","key":"2026090108010904000_cit9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev.pa.35.040195.000521","article-title":"Molecular\nMechanisms and Therapeutic Approaches to the Treatment of African\nTrypanosomiasis","volume":"35","author":"Wang","year":"1995","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2026090108010904000_cit10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-308X(01)49037-3","article-title":"Antigenic variation in trypanosomes: Enhanced phenotypic\nvariation in a eukaryotic parasite","volume":"49","author":"Barry","year":"2001","journal-title":"Advances\nin Parasitology"},{"issue":"12","key":"2026090108010904000_cit11","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1371\/journal.pntd.0000333","article-title":"The Burden\nof Human\nAfrican Trypanosomiasis","volume":"2","author":"Fevre","year":"2008","journal-title":"PLoS Neglected Trop.\nDis."},{"key":"2026090108010904000_cit12","first-page":"595","article-title":"The effects of trypanosomiasis\non rural economy*","volume":"28","author":"Wilson","year":"1963","journal-title":"Bull World Health Organ"},{"key":"2026090108010904000_cit13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.pt.2003.09.002","article-title":"Chemotherapy\nof human African trypanosomiasis: Current and future prospects","volume":"19","author":"Fairlamb","year":"2003","journal-title":"Trends Parasitol."},{"key":"2026090108010904000_cit14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-308X(08)60410-8","article-title":"The treatment of human African trypanosomiasis","volume":"33","author":"Pe\u0301pin","year":"1994","journal-title":"Adv. Parasitol."},{"issue":"2","key":"2026090108010904000_cit15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical\nfeatures, diagnosis, and treatment of human African trypanosomiasis\n(sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"issue":"S1","key":"2026090108010904000_cit16","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the\ntreatment of human African trypanosomiasis.","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitol. Res."},{"key":"2026090108010904000_cit17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0031182016002109","article-title":"The trypanosome\nalternative oxidase: a potential drug target?","author":"Menzies","year":"2016","journal-title":"Parasitology"},{"issue":"2\u20133","key":"2026090108010904000_cit18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0925-4439(02)00086-8","article-title":"Trypanosome alternative oxidase as\na target of chemotherapy","volume":"1587","author":"Nihei","year":"2002","journal-title":"Biochim. Biophys.\nActa, Mol. Basis Dis."},{"issue":"1","key":"2026090108010904000_cit19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0166-6851(98)00091-7","article-title":"Biochemical\nand molecular properties\nof the Trypanosoma brucei alternative oxidase","volume":"95","author":"Chaudhuri","year":"1998","journal-title":"Mol. Biochem. Parasitol."},{"issue":"3","key":"2026090108010904000_cit20","doi-asserted-by":"publisher","first-page":"e1006307","DOI":"10.1371\/journal.ppat.1006307","article-title":"Aquaglyceroporin-null trypanosomes\ndisplay glycerol transport defects\nand respiratory-inhibitor sensitivity","volume":"13","author":"Jeacock","year":"2017","journal-title":"PLoS\nPathog."},{"issue":"Pt 3","key":"2026090108010904000_cit21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1107\/S1744309109054062","article-title":"Crystallization and preliminary crystallographic\nanalysis of cyanide-insensitive alternative oxidase from Trypanosoma\nbrucei brucei","volume":"66","author":"Kido","year":"2010","journal-title":"Acta Crystallogr., Sect. F: Struct.\nBiol. Cryst. Commun."},{"issue":"3","key":"2026090108010904000_cit22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jb\/mvs135","article-title":"Pharmacophore\nidentification of ascofuranone, potent inhibitor of cyanide-insensitive\nalternative oxidase of Trypanosoma brucei","volume":"153","author":"Saimoto","year":"2013","journal-title":"J.\nBiochem."},{"key":"2026090108010904000_cit23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejmech.2017.09.067","article-title":"African\ntrypanosomiasis\u202f: Synthesis & SAR enabling novel drug discovery\nof ubiquinol mimics for trypanosome alternative oxidase","volume":"141","author":"West","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"2026090108010904000_cit24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.parint.2005.09.003","article-title":"Chemotherapeutic\nefficacy\nof ascofuranone in Trypanosoma vivax-infected mice without glycerol","volume":"55","author":"Yabu","year":"2006","journal-title":"Parasitol. Int."},{"issue":"1","key":"2026090108010904000_cit25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain\nbarrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"6","key":"2026090108010904000_cit26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond Rules: The Development\nof a Central Nervous System Multiparameter Optimization (CNS MPO)\nApproach To Enable Alignment of Druglike Properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"13","key":"2026090108010904000_cit27","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1021\/jo00953a006","article-title":"Physical organic\nchemistry of benzisoxazoles. I. Mechanism of the base-catalyzed decomposition\nof benzisoxazoles","volume":"38","author":"Casey","year":"1973","journal-title":"J. Org. Chem."},{"issue":"11","key":"2026090108010904000_cit28","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1246\/bcsj.60.4187","article-title":"Halogenation\nUsing Quaternary Ammonium Polyhalides. IV. Selective Bromination of\nPhenols by Use of Tetraalkylammonium Tribromides","volume":"60","author":"Kajigaeshi","year":"1987","journal-title":"Bull. Chem. Soc. Jpn."},{"issue":"14","key":"2026090108010904000_cit29","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1021\/acs.orglett.5b01720","article-title":"A Concise\nand Atom-Economical Suzuki\u2013Miyaura Coupling Reaction Using\nUnactivated Trialkyl- and Triarylboranes with Aryl Halides","volume":"17","author":"Li","year":"2015","journal-title":"Org. Lett."},{"issue":"6","key":"2026090108010904000_cit30","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/op900231j","article-title":"Development\nof a Scalable Synthetic Process\nfor DG-051B, A First-in-Class Inhibitior of LTA4H","volume":"13","author":"Enache","year":"2009","journal-title":"Org. Process Res. Dev."},{"issue":"22","key":"2026090108010904000_cit31","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1016\/j.tetlet.2007.03.146","article-title":"A convenient\naminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene\n(TBD) under solvent-free conditions","volume":"48","author":"Sabot","year":"2007","journal-title":"Tetrahedron\nLett."},{"issue":"15","key":"2026090108010904000_cit32","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1016\/j.bmcl.2009.05.062","article-title":"Rapid assessment\nof a novel series of selective CB2 agonists using parallel synthesis\nprotocols: A Lipophilic Efficiency (LipE) analysis","volume":"19","author":"Ryckmans","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"2026090108010904000_cit33","doi-asserted-by":"publisher","first-page":"8849","DOI":"10.1021\/jm4012774","article-title":"Design, Synthesis, and\nBiological Evaluation of Indole-2-carboxamides: A Promising Class\nof Antituberculosis Agents","volume":"56","author":"Kondreddi","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026090108010904000_cit34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejmech.2015.10.008","article-title":"Structure activity relationships of 4-hydroxy-2-pyridones:\nA novel class of antituberculosis agents","volume":"106","author":"Ng","year":"2015","journal-title":"Eur.\nJ. Med. Chem."}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.7b00218","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/4\/4\/592\/67429149\/acsinfecdis.7b00218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/4\/4\/592\/67429149\/acsinfecdis.7b00218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:01:13Z","timestamp":1788264073000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/4\/4\/592\/845372\/Toward-More-Drug-Like-Inhibitors-of-Trypanosome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,21]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,1,21]]},"published-print":{"date-parts":[[2018,4,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.7b00218","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,21]]}}}